Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
Pratishtha Chatterjee, Steve Pedrini, Erik Stoops, et al.
Translational Psychiatry (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 323

Showing 1-25 of 323 citing articles:

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 496
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Ahmed Abdelhak, Matteo Foschi, Samir Abu‐Rumeileh, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 3, pp. 158-172
Open Access | Times Cited: 470
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum
Andréa Lessa Benedet, Marta Milà‐Alomà, Agathe Vrillon, et al.
JAMA Neurology (2021) Vol. 78, Iss. 12, pp. 1471-1471
Open Access | Times Cited: 379
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Charlotte E. Teunissen, Inge M.W. Verberk, Elisabeth H. Thijssen, et al.
The Lancet Neurology (2021) Vol. 21, Iss. 1, pp. 66-77
Open Access | Times Cited: 356
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
Joana B. Pereira, Shorena Janelidze, Ruben Smith, et al.
Brain (2021) Vol. 144, Iss. 11, pp. 3505-3516
Open Access | Times Cited: 339
Identifying phenotype-associated subpopulations by integrating bulk and single-cell sequencing data
Duanchen Sun, Xiangnan Guan, Amy E. Moran, et al.
Nature Biotechnology (2021) Vol. 40, Iss. 4, pp. 527-538
Open Access | Times Cited: 269
Blood‐based biomarkers for Alzheimer's disease
Antoine Leuzy, Niklas Mattsson, Sebastian Palmqvist, et al.
EMBO Molecular Medicine (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 219
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
Claudia Cicognola, Shorena Janelidze, Joakim Hertze, et al.
Alzheimer s Research & Therapy (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 202
Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
Bruna Bellaver, Guilherme Povala, Pâmela C.L. Ferreira, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1775-1781
Open Access | Times Cited: 166
Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease
Pratishtha Chatterjee, Steve Pedrini, Nicholas J. Ashton, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 6, pp. 1141-1154
Open Access | Times Cited: 159
Characterization of pre‐analytical sample handling effects on a panel of Alzheimer's disease–related blood‐based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group
Inge M.W. Verberk, Els O. Misdorp, Jannet Koelewijn, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 8, pp. 1484-1497
Open Access | Times Cited: 152
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease
Michael J. Pontecorvo, Ming Lu, Samantha Burnham, et al.
JAMA Neurology (2022) Vol. 79, Iss. 12, pp. 1250-1250
Open Access | Times Cited: 151
Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohort
Pratishtha Chatterjee, Steve Pedrini, James D. Doecke, et al.
Alzheimer s & Dementia (2022) Vol. 19, Iss. 4, pp. 1117-1134
Open Access | Times Cited: 139
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy
Leonidas Chouliaras, Alan Thomas, Maura Malpetti, et al.
Journal of Neurology Neurosurgery & Psychiatry (2022) Vol. 93, Iss. 6, pp. 651-658
Open Access | Times Cited: 129
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Ka Young Kim, Ki Young Shin, Keun‐A Chang
Cells (2023) Vol. 12, Iss. 9, pp. 1309-1309
Open Access | Times Cited: 128
PET Imaging of Neuroinflammation in Alzheimer’s Disease
Rong Zhou, Bin Ji, Yanyan Kong, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 119
Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape
Harald Hampel, Yan Hu, Jeffrey L. Cummings, et al.
Neuron (2023) Vol. 111, Iss. 18, pp. 2781-2799
Open Access | Times Cited: 118
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease
Joshua Stevenson‐Hoare, Amanda Heslegrave, Ganna Leonenko, et al.
Brain (2022) Vol. 146, Iss. 2, pp. 690-699
Open Access | Times Cited: 113
Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases
Andrew Chang, Xinyu Xiang, Jing Wang, et al.
Cell (2022) Vol. 185, Iss. 8, pp. 1346-1355.e15
Open Access | Times Cited: 109
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
Andréa Lessa Benedet, Wagner S. Brum, Oskar Hansson, et al.
Alzheimer s Research & Therapy (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 95
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
Abby L. Brand, Paige E. Lawler, James G. Bollinger, et al.
Alzheimer s Research & Therapy (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 92
Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology
Dror Shir, Jonathan Graff‐Radford, Ekaterina I. Hofrenning, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 85
Plasma Biomarkers of Alzheimer’s Disease: A Review of Available Assays, Recent Developments, and Implications for Clinical Practice
Marcos Vasconcelos Pais, Orestes Vicente Forlenza, Breno S. Diniz
Journal of Alzheimer s Disease Reports (2023) Vol. 7, Iss. 1, pp. 355-380
Open Access | Times Cited: 64
Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers
Hannah Stocker, Léon Beyer, Kira Trares, et al.
JAMA Network Open (2023) Vol. 6, Iss. 1, pp. e2252387-e2252387
Open Access | Times Cited: 57
Blood Biomarkers in Neurodegenerative Diseases
Daniel Alcolea, Michal Schnaider Beeri, Julio C. Rojas, et al.
Neurology (2023) Vol. 101, Iss. 4, pp. 172-180
Closed Access | Times Cited: 45
Page 1 - Next Page

Scroll to top